Advertisement

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.
Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available.

 

Announcing our new Impact Factor: 11.151!

From the Current Issue

  • Research Articles
    An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
    Yuanming Xu, Lucia Campos Carrascosa, Yik Andy Yeung, Matthew Ling-Hon Chu, Wenjing Yang, Ivana Djuretic, Danielle C. Pappas, John Zeytounian, Zhouhong Ge, Valeska de Ruiter, Gabriel R. Starbeck-Miller, James Patterson, Diamanda Rigas, Shih-Hsun Chen, Eugenia Kraynov, Patrick P. Boor, Lisanne Noordam, Michael Doukas, Dave Tsao, Jan N. Ijzermans, Jie Guo, Dirk J. Grünhagen, Joris Erdmann, Joanne Verheij, Martin E. van Royen, Pascal G. Doornebosch, Renny Feldman, Terrence Park, Salah Mahmoudi, Magdalena Dorywalska, Irene Ni, Sherman M. Chin, Tina Mistry, Lidia Mosyak, Laura Lin, Keith A. Ching, Kevin C. Lindquist, Changhua Ji, Luz Marina Londono, Bing Kuang, Robert Rickert, Jaap Kwekkeboom, Dave Sprengers, Tzu-Hsuan Huang and Javier Chaparro-Riggers
    Cancer Immunol Res October 1 2021 9 (10) 1141-1157; DOI:10.1158/2326-6066.CIR-21-0058

    To overcome challenges associated with cytokine-based immunotherapies, the authors engineered a fusion protein of a single, potency-reduced, IL15 mutein and a PD1-specific antibody. The agent preferentially activates intratumoral CD8+ T cells and demonstrates potent preclinical antitumor efficacy.

  • Research Articles
    Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
    Yanping Yang, Jaclyn E. McCloskey, Huan Yang, Janusz Puc, Yago Alcaina, Yogindra Vedvyas, Angel A. Gomez Gallegos, Elizabeth Ortiz-Sánchez, Elisa de Stanchina, Irene M. Min, Eric von Hofe and Moonsoo M. Jin
    Cancer Immunol Res October 1 2021 9 (10) 1158-1174; DOI:10.1158/2326-6066.CIR-21-0062

    Generation of EpCAM/ICAM-1 dual CAR T cells improves the efficacy of single-targeting EpCAM CAR T cells in multiple tumor models. The data highlight a broadly applicable strategy to boost the activity of single antigen-specific CAR T-cell therapy.

OnlineFirst Articles

Load more

Trending - Altmetric

Advertisement

Back to top